Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to Interferon-Gamma-Neutralizing Antibody, EI 001 for the Treatment of Hemophagocytic Lymphohistiocytosis

The U.S. FDA has granted Orphan Drug Designation to our interferon-gamma-neutralizing antibody, EI-001 for the treatment of hemophagocytic lymphohistiocytosis, a life-threatening disease in children and adults requiring aggressive intervention to control the symptoms that are driven in large part by aberrant or excessive interferon-gamma production. Read our press release here

The release as fetched from its publisher. elixiron.com ↗